😍 Why the Market Loves the Rising Chance of a Recession

Good morning. In financial markets, good news is often bad news. And bad news is often good news... It’s the monthly jobs numbers today and they’re not going to be pretty and will be possibly the tip of the iceberg as we head into May. [Trading Tips] Good morning. In financial markets, good news is often bad news. And bad news is often good news. While it seems counterintuitive, the logic is simple. If the economy is in poor shape, it will be supported by lower interest rates (cheaper money), and potentially even increased fiscal stimulus (things like direct payments). That’s good for asset prices in the short-term. Right now, rising alarm bells over a recession, which we’re likely already in, have turned this bad news into good news, with markets slightly up for the week. The news isn’t bad enough to slow down the Federal Reserve yet. But the narrative is growing that the Fed will stop raising rates sooner than expected, and will likely cut rates sooner than expected as well. Until that actually happens, however, investors and traders alike need to be strategic, and be willing to play both sides of what will remain a volatile market. Now here's the rest of the news: Sponsored Content [Invest In This Biotech Company Solving A $240B Problem]( Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These “band-aid” therapies are temporary and do not treat the root cause of osteoarthritis. [Enter Cytonics.]( This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called “A2M,” to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients’ quality of life. Backed by Johnson & Johnson and the NIH, [Cytonics]( is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, “CYT-108,” has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies. Cytonics’ first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. [Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public.]( MARKETS DOW 30,677.36 +0.64% S&P 3,795.73 +0.95% NASDAQ 11,232.19 +1.62% *As of market close • Stocks closed higher on Thursday, shaking off a mid-day drop. • Oil dropped 2.1 percent, closing at $104.00 per barrel. • Gold declined 0.6 percent, going for $1,828 per ounce. • Cryptocurrencies moved slightly higher, with Bitcoin at $20,879 at the market close Today’s TOP TIPS [Keep Accumulating Industry Leaders While the Market Fear Continues]( With the stock market in the throes of a bear pullback, many are looking to history as a guide for when the bear will end. While the answer varies, chances are stocks will remain weak for a few more weeks and even months as economic data continues to come in. That said, investors who start accumulating shares of great companies, particularly industry-leading companies, will end up with a strong portfolio performance on the market’s next rally higher. » [FULL STORY]( [Insider Trading Report: Analog Devices (ADI)]( Bruce Evans, a director at Analog Devices (ADI), recently picked up 3,650 shares. The buy increased his stake by 3.6 percent, and came to a total price just over $526,000. This marks the first insider buy at the company since last October. Company insiders, including c-suite executives and directors, have been regular sellers of shares of the semiconductor firm over the past three years, with only a few buys from insiders. » [FULL STORY]( [Unusual Options Activity: BP (BP)]( Shares of oil and gas giant BP (BP) have slid in recent days. One trader sees the possibility for a rebound into the start of next year. That’s based on the January 2023 $31 calls. With 210 days until expiration, 6,511 contracts traded compared to an open interest of 125, for a 52-fold rise in volume on the trade. The buyer of the calls paid $2.10 to get into the trade. » [FULL STORY]( IN OTHER NEWS • [Mortgage Rates Resume Their Rise]( 30-year, fixed-rate mortgages averaged 5.8 percent for this week, a slight gain over the 5.78 percent the week before. That’s as high as in late 2008, and is nearly double the 3.02 percent rate just one year ago. Mortgage rates tie directly into the costs of homeownership, and rapidly-rising rates are likely to lead to a slowdown in sales and home prices in the months ahead. • [US Natural Gas Sales to Europe Rise as Sales to China Drop]( In the last year, sales of natural gas from the US to China have dried up, as China is now buying natural gas supplies from Russia. However, thanks to trade restrictions from Russia’s invasion of Ukraine, natural gas sales from the US to Europe are on the rise. • [Corporate Borrowing Slows as Rates Rise]( No US company has issued corporate debt in the past week, according to Bank of America (BAC). And companies in general have slowed down their borrowing activity in the past month. The move comes as interest rates have started to rise, which increases the cost of borrowing money. • [FDA Bans Juul E-Cigarettes]( The FDA has rejected an application from Juul to sell e-cigarettes in the United States. The company needs to stop selling and distributing its products. This follows up from the agency’s 2020 ban on mint and fruit-flavored vaping products to cut down on teen vaping use. • [Facebook Pay Rebrands for the Metaverse]( Facebook Pay is rebranding to Meta Pay. The move comes months after the company renamed itself Meta Platforms (META). The goal is to refocus the product on integration with the Metaverse, where real money can be used to purchase digital goods. S&P 500 MOVERS TOP ADSK 8.43% FDS 8.007% CDAY 7.241% WHR 7.055% ALGN 6.819% BOTTOM MOS 9.574% CF 9.009% VLO 7.602% ADM 7.336% SLB 6.77% Quote of the Day The odds are more likely in favor of a recession than not. That speaks to the degree of tightening that the Federal Reserve is going to have to do now, having not done so in prior periods when perhaps they would have avoided some of the problems that are going to happen as a result. Unfortunately, it’s going to be more economic pain than people at least six months ago anticipated, but are increasingly coming around to the reality that that’s probably what’s going to happen. - Dan Greenhaus, Solus Alternative Asset Management chief strategist, on why the economy is sliding into a recession and why investors should expect markets to continue to be volatile and toward the downside. Sponsored Content [Invest In This Biotech Company Solving A $240B Problem]( Every year, over 600M patients suffering from osteoarthritis spend $240 billion on painkillers and other palliative solutions to the cartilage damage caused by this debilitating disease. These “band-aid” therapies are temporary and do not treat the root cause of osteoarthritis. [Enter Cytonics.]( This private biotech startup has harnessed the therapeutic potential of a naturally occurring blood protein, called “A2M,” to reverse cartilage deterioration in arthritic joints. Their first FDA approved A2M-based therapy has successfully treated over 8,000 patients, proving the therapeutic efficacy of A2M, and restoring patients’ quality of life. Backed by Johnson & Johnson and the NIH, [Cytonics]( is developing a genetically engineered A2M variant that is more potent than the natural form. This lead drug candidate, “CYT-108,” has been proven to restore up to 80% of cartilage damage caused by osteoarthritis in preclinical studies. Cytonics’ first-in-in-class CYT-108 will enter Phase 1 clinical trials later this year. [Invest in Cytonics as they blaze toward their second FDA drug approval, and before this private biotech goes public.]( Not sure the best way to get started? Follow these simple steps to hit the ground running. › Step #1 - Get These FREE Reports: [Warren Buffett's Top 5 Stocks]( | [10 Great Stocks Under $10]( | [7 High Yield Dividend Stocks]( › Step #2 - Join Our Premium Advisory: [The Next Superstock]( › Step #3 - Claim Your Free Copy Of: [Big Book Of Chart Patterns]( | [How to Trade Weekly Options For Weekly Income]( We just wanted to take a moment and say thank you so much for being part of our family! We are dedicated to teaching people how to make the world a better place so we can all thrive, together. We love sharing stories and featuring past learners who have applied our teachings and changed their situations. It’s our passion to build a strong community centered around fun and mindset! We love to discover extraordinary and useful tools and share them with the world! We create a space where people can discover how to enjoy their lives by simply choosing to learn. Every day we are building and strengthening partnerships with our customers and clients and we do so in the most ethical way possible. We particularly love working with artisans, makers, and small businesses because through their passion and their craft they help make the world a better place.. Without all of you we wouldn't be able to do what we do on a daily basis and for that we say thank you. We've been living our dream for many years now and that wouldn't be possible without every single one of you. The idea of going from a typical nine to five life to a life of freedom doesn’t seem real to most people, but we want you to know it is definitely possible. We’ve done it. You have the power to control your life, your actions, and what you choose to focus on. We’re here to help you along that journey to achieve whatever goals you set out for yourself. However, we also care about keeping you and your privacy safe. We are committed to advising you of the right to your privacy. We strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website. It also explains how we collect and use non-personal information. By accessing and using our website, you explicitly accept, without limitation or qualification, the collection, use and transfer of the personal information and non-personal information in the manner described in this Privacy Policy. Please read this Policy carefully, as it affects your rights and liabilities under the law. If you disagree with the way we collect and process personal and non-personal information, please do not use this website. This Policy applies to this website as well as all webpages Company hosts. It regulates the processing of information relating to you and grants both of us various rights with respect to your personal data. It also informs you of how to notify us to stop using your personal information. We are located in the United States of America. You may be located in a country that has laws which are more restrictive about the collection and use of your personal information. However, by using our website, you agree to waive the more restrictive laws and agree to be governed by the laws of the United States of America. If you wish to view our privacy policy, you can find it below. Nothing in this email should be considered personalized financial advice. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions. As defined in the United States Securities Act of 1933 Section 27(a), as amended in the Securities Exchange Act of 1934 Section 21(e), statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.  This email was sent to {EMAIL} by editor@tradingtips.com TradingTips.com | 3435 Ocean Park Blvd. Suite 107-334 Santa Monica, CA 90405 [Manage Subscriptions]( | [report SPAM]( Â